A population-based cohort study published in JAMA Dermatology compared cancer incidence among 6,181 patients with morphea and 8,133 with systemic sclerosis (SSc), using health data from Quebec, Canada. During follow-up, cancer developed in 12.65% of patients with morphea and 13.57% with SSc. Overall cancer incidence was higher than expected in both groups (morphea SIR, 1.24; 95% CI, 1.14-1.35; SSc SIR, 1.37; 95% CI, 1.27-1.48).Solid tumor incidence was elevated in both conditions.
However, hematologic cancer risk was significantly increased in SSc (SIR, 2.40), but not in morphea (SIR, 1.34; 95% CI, 0.97-1.81).Breast and female reproductive cancers predominated in morphea, while lung cancer was most frequent in SSc. Younger patients had the highest relative risk. Morphea was associated with increased overall and solid tumor incidence, challenging the assumption that cancer risk isβ¦